PFG
VRTX icon

Piershale Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Piershale Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$4.73K – 300
2023
Q1 		$4.73K Hold
15
– – ﹤0.01% 175
2022
Q4 		$4.33K Buy
+15
New +$4.57K ﹤0.01% 193

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Piershale Financial Group's VRTX Position: Q2 2023 in Review

Piershale Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 15 shares — an estimated $4.73K sold.

Piershale Financial Group first reported a position in VRTX in Q4 2022 and held it in 2 quarters. The position peaked at $4.73K in Q1 2023. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • Piershale Financial Group reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Piershale Financial Group sold 15 Vertex Pharmaceuticals shares in Q2 2023, an estimated $4.73K.
  • Piershale Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Piershale Financial Group's Vertex Pharmaceuticals position peaked at $4.73K in Q1 2023.
  • 1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.